Roots Analysis

AUGUST 7, 2023

On the other hand, cell free system / cell free expression system are ­in-vitro platforms that harness the transcription and translation machinery of living cells, in the form of cell lysates, to synthesize various types of biologics, particularly proteins. Interestingly, most of these kits are used for cell-free protein expression.

Marketing 52

Marketing Protein In-Vitro Production 52

Roots Analysis

AUGUST 15, 2023

Overview of Cell Free Systems Cell-free systems are ­in-vitro platforms which allow occurrence of biochemical reactions in the absence of living cells. Additionally, these types of cell free systems do not contain proteases and nucleases as crude cell lysates, which further helps in improving the production of many proteins.

Protein 52

Protein In-Vitro Production Reagent 52

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What data did you present at the conference?

RNA 64

RNA In-Vivo In-Vitro DNA 64

Drug Discovery World

AUGUST 9, 2022

Based in Dundee, Cypex manufactures recombinant xenobiotic metabolizing enzymes with its product portfolio covering a wide range of proteins involved in drug metabolism. . This technology enables the expression of human drug-metabolizing enzymes in bacteria, without requiring large modifications to the proteins.? .

In-Vitro 52

In-Vitro Protein Production Bacteria 52

Bioengineer

JANUARY 16, 2024

This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP binding site, overcoming resistance mechanisms. In the same study, those with T790M loss had a shorter treatment duration (6.1 months vs. 15.2

Genome 119

Genome Genomics Protein In-Vitro 119

Pharmaceutical Technology

FEBRUARY 23, 2023

Innovation S-curve for artificial Intelligence in the pharmaceutical industry In-silico drug discovery is a key innovation area in artificial Intelligence Drug research starts with the discovery stage that involves in vivo and in vitro models to shortlist lead drug compounds.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

Pharmaceutical Technology

AUGUST 11, 2022

There is a clear correlation between the INHBE gene and metabolic syndrome, particularly T2D and coronary heart disease, and the potential development of targeted therapy in future could have broad benefits across these disorders.

Gene 130

Gene Biobanking Gene Expression In-Vitro 130

pharmaphorum

DECEMBER 1, 2022

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Billion by 2028. Billion by 2028. Event Hashtag: #3DCellCulture2023.

In-Vitro 52

In-Vitro Engineer Scientist Gene Therapy 52

Drug Discovery World

JANUARY 25, 2024

The research, funded by a grant from the State of Florida, aims to develop Vaxxinity’s active immunotherapies to prevent and mitigate muscle and bone wasting. US company Vaxxinity and the University of Central Florida (UCF) have announced plans to work together to advance space medicine research.

Medicine 52

Medicine Research In-Vivo In-Vitro 52

XTalks

FEBRUARY 1, 2023

The researchers found that factors in the blood can potentially predict the risk of developing the disease years before a clinical diagnosis is made. Some Alzheimer’s patients start off by developing mild cognitive impairment (MCI), which is a condition that involves worsening memory or cognitive ability.

Research 98

Research In-Vitro Protein Development 98

XTalks

APRIL 13, 2021

While it has been known for about five decades now that patients with Parkinson’s disease have a higher likelihood of developing melanoma than the general population, the exact reasons for this were unknown. The scientists found that the amyloid-forming protein is expressed at higher levels in melanoma cells than in normal healthy skin.

Research 98

Research Protein In-Vitro Gene Therapy 98

Drug Discovery World

JANUARY 23, 2023

Ubiquigent is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a (de)ubiquitylation (DUB) implicated in neurodegenerative, renal, and cardiovascular diseases. Overseen by Professor Helen Walden, UoG, and Dr Mehmet Gundogdu, Principal Scientist at Ubiquigent, the project aims to combine biochemistry, (..)

In-Vitro 52

In-Vitro Protein Regulation Scientist 52

Drug Discovery World

JUNE 27, 2023

The collaboration has taken advantage of these novel technologies to develop peptide candidates that progress into the clinic. “At Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area.

In-Vivo 52

In-Vivo In-Vitro Engineer Protein 52

Roots Analysis

JANUARY 14, 2024

With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally. They are different from small molecules in terms of their size and complexity.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Protein Bacteria 40

Drug Discovery World

JANUARY 17, 2024

Scientists from Fujita Health University have shown that mitochondria play essential roles during muscle development, regeneration and maintenance. The research team conducted experiments involving ‘Mitofusin2’ (MFN2), a protein that is necessary for mitochondria tethering in MAMs.

In-Vitro 52

In-Vitro Regulation Protein Gene 52

pharmaphorum

JANUARY 18, 2022

Developing Complex, Translatable and Physiologically-Relevant Cellular Models in vitro. Key Benefits of Attending: • Discuss the uses of advanced cell technologies to construct in vitro models of human tissues. Sponsored by: CELLINK, CelVivo, Promega and Newcells Biotech. 2 Interactive Workshops on 8th February 2022.

In-Vitro 52

In-Vitro Engineer Drugs Pharma Companies 52

Drug Discovery World

MARCH 8, 2023

BAT8008 was developed by using Bio-Thera Solutions’ ADC linker-payload that includes a cleavable but systemically stable linker, a small molecule topoisomerase I inhibitor and high DAR. The small molecule topoisomerase I inhibitor payload carried by BAT8008 has a strong cell membrane penetration ability.

Trials 52

Trials In-Vivo In-Vitro Antibody 52

pharmaphorum

JANUARY 22, 2021

According to the US biopharma company, genetic analyses of publicly available sequences for the new variants of SARS-CoV-2 suggest the mutations in the viral spike protein that have made them more transmissible shouldn’t affect the way Veklury (remdesivir) works. The UK strain – known as B.1.1.7

In-Vitro 141

In-Vitro RNA Licensing Licensing 141

XTalks

APRIL 18, 2024

This test, which is being co-developed with Eli Lilly, has the potential to facilitate earlier and more accurate detection of the disease. The Elecsys pTau217 assay is designed to detect amyloid pathology, a hallmark of Alzheimer’s disease, by measuring phosphorylated tau protein in human plasma.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

XTalks

JANUARY 6, 2021

One nanobody in particular, called NIH-CoVnb-112, was shown to be able to prevent COVID-19 infection from the novel coronavirus by targeting both the spike protein on SARS-CoV-2, as well as the angiotensin converting enzyme 2 (ACE2) receptor that it binds to on human cells. The study was led by neuroscientists Thomas J. “TJ”

Antibody 105

Antibody Protein Bacteria In-Vitro 105

The Pharma Data

JANUARY 16, 2021

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform. JS Bio’s parent company.

Protein 52

Protein Production Antibody In-Vitro 52

Drug Discovery World

MARCH 23, 2023

iOnctura, a clinical stage biotechnology company developing cancer therapies, has published non-clinical research on roginolisib in the AACR journal Cancer Research Communications. Consistent with first-generation PI3Kdinhibitors, roginolisib inhibits the in vitro growth of lymphoma cells.

Research 98

Research In-Vitro Clinical Research Genome 98

XTalks

JULY 22, 2021

We’ve heard of cell-based meat — meat produced by in vitro cell cultures of animal cells — but its seafood equivalent could be on the horizon. Cell-based fish has been making a splash in recent years, with several alt-seafood companies making the semi-finals of a recent alternative protein competition. Benefits of Cell-Based Fish.

Protein 96

Protein In-Vitro Production Marketing 96

The Pharma Data

MARCH 31, 2023

“Just like ChatGPT uses data from written language to create predictive text, we are leveraging the language of proteins to predict their activity,” said study leader Huimin Zhao, a University of Illinois Urbana-Champaign professor of chemical and biomolecular engineering. Woese Institute for Genomic Biology at Illinois.

Protein 40

Protein Genome Genomics Engineer 40

XTalks

JUNE 30, 2023

But to meet aggressive milestones and stringent performance standards, there’s a need for continuous innovation and streamlined development and quality control workflows. Sartorius is a globally recognized player in the diagnostics industry, providing a variety of solutions for in vitro diagnostics kit (IVD) manufacturers.

In-Vitro 52

In-Vitro Manufacturing Production Antibody 52

The Pharma Data

APRIL 7, 2021

today announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. p53 is protein which, when active, helps to regulate processes which stop tumors from developing. p53 is protein which, when active, helps to regulate processes which stop tumors from developing.

In-Vitro 52

In-Vitro Antibody Genetics Protein 52

Drug Discovery World

APRIL 3, 2023

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

XTalks

APRIL 6, 2022

The personalized ctDNA blood test uses the RaDaR™ assay, a liquid biopsy platform developed by the company Inivata. Register for this webinar to get an overview of the role of long non-protein coding RNAs (lncRNAs) in gene regulations. Photo source: Inivata. Around 85 percent of cases are non-small cell lung cancer (NSCLC).

DNA 105

DNA In-Vitro Doctors Doctor 105

The Pharma Data

FEBRUARY 25, 2022

“The SARS-CoV-2 vaccines target the spike protein, but this protein is under strong selection pressure and, as we have seen with Omicron, can undergo significant mutations,” said Joyce Jose, assistant professor of biochemistry and molecular biology, Penn State. ” The findings published today (Feb.

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

XTalks

JANUARY 27, 2021

The company used in vitro neutralization antibody studies to evaluate the activity of Moderna’s vaccine-generated antibodies in human sera against several variants of the novel coronavirus, including the B.1.1.7 The in vitro study evaluated the ability of mRNA-1273-generated antibodies to neutralize the new SARS-CoV-2 variants.

Vaccination 52

Vaccination Vaccine In-Vitro Protein 52

The Pharma Data

MAY 31, 2022

Roche’s Chief Medical Officer and Head of Global Product Development. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Evrysdi is now approved in the US to treat SMA in children and adults of all ages. Jude Children’s Research Hospital.

FDA Approval 52

FDA Approval Protein In-Vitro Medicine 52

Drug Discovery World

JANUARY 23, 2023

This action sensitised GBM cells to radiotherapy both in vitro and in vivo (in mouse models). “Our research has revealed cladribine as a radiosensitiser for GBM treatment by drug repurposing, which can offer multiple advantages,” says Prof Youn. “As GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

XTalks

MARCH 6, 2024

Brain Awareness Week 2024 , taking place March 11 to 17 this year, is a global campaign that aims to demystify the complexities of the human brain and promote the significance of neuroscientific research. This relates to neurological conditions like dementia and Alzheimer’s disease, which account for up to 70 percent of dementia cases.

FDA Approval 69

FDA Approval In-Vitro Research Marketing 69

pharmaphorum

JANUARY 17, 2023

As it stands, mRNA vaccines and therapeutics can only provide benefits if they can reach the living cells and be processed into protein. Ben Hargreaves speaks to Liberate Bio, a company that is hoping to address the delivery issues that could prevent mRNA, as well as siRNA and ASO therapeutics, from reaching their full potential.

Vaccination 97

Vaccination Vaccine In-Vivo In-Vitro 97

pharmaphorum

NOVEMBER 9, 2022

A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed. In ALS , the protein TDP-43 triggers neuroinflammation via activation of the innate immune sensor STING. It has been supporting NRG’s work since 2019.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Recombinant therapeutic proteins. Fusion proteins. Gene and cellular therapies. Growth factors. Interferons.

Development 180

Development Protein Production Hormones 180